

## **Ongoing Disclosure Notice**

To NZX Limited; and Name of listed issuer:

## **Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

Date this disclosure made:	16-Jun-23
Date of last disclosure:	2-Jul-20
Director or senior manager giving disclosure	
Full name(s):	Robert Clyde McConaghy
Name of listed issuer:	Serko Limited
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)	
Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
That are of the arrested relevant meeters, (9).	of shares by virtue of Mr McConaghy
	being a trustee (and beneficiary of) the
	Portofino Trust).
For that relevant interest-	Tortonno Trusty.
Number held in class before acquisition or disposal:	181,818
Number held in class after acquisition or disposal:	146,818
Current registered holder(s):	Robert Clyde McConaghy as Trustee of
Current registered noticer(s).	Portofino Trust
Registered holder(s) once transfers are registered:	Unknown
negistered florder(s) office transfers are registered.	OTIKTOWIT
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	2
Details of transactions requiring disclosure-	2
Date of transaction:	1) 13 June 2023
Date of transaction.	2) 14 June 2023.
Nature of transaction:	-
Nature of transaction.	Two separate market (ASX) sell transactions
	transactions
Name of any other party or parties to the transaction (if known):	Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or	1) 21,621 ordinary shares: \$69,546.28
disposal. If the consideration was not in cash and cannot be readily by converted into a cash	AUD x FX rate 1.10 (2dp) = \$76,500.91
value, describe the consideration:	NZD (2dp)
value, describe the consideration.	(2dp)
	2) 12 270 ordinary shares; \$42 491 75 y
	2) 13,379 ordinary shares: \$43,481.75 x
	FX rate 1.10 ( 2 dp) = \$47,829.93 NZD
	(2dp)
	Total NZD consideration: \$124,330.84
Number of financial products to which the transaction related:	35,000
If the issuer has a financial products trading policy that prohibits directors or senior	
managers from trading during any period without written clearance (a closed period) include	
the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed	Not applicable
during the closed period:	
Date of the prior written clearance (if any):	Not applicable
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary shares
Nature of relevant interest:	Registered holder and beneficial owner
For that relevant interest,-	
Number held in class:	1,091
Current registered holder(s):	Robert Clyde McConaghy
For a derivative relevant interest,-	
Type of derivative:	Not applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial	Not applicable
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	Not applicable
Maturity date of the derivative (if any):	Not applicable
Expiry date of the derivative (if any):	Not applicable

Serko Limited

The price's specified terms (if any):	Not applicable
Any other details needed to understand how the amount of the consideration payable under	Not applicable
the derivative or the value of the derivative is affected by the value of the underlying	
financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant	Not applicable
interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all persons for	
whom it is made.	
Signature of director or officer:	11011 001

16-Jun-23

Date of signature: